Identification of a novel tedizolid resistance mutation in rpoB of methicillin-resistant Staphylococcus aureus

A tedizolid-resistant isolate of MRSA was selected by serial passage. Whole genome sequencing revealed only a single nucleotide variant in rpoB. Cross-resistance to linezolid, chloramphenicol, and quinupristin-dalfopristin was observed but susceptibility to other drugs including rifampin was unchanged. Models of the RNA-polymerase-ribosomal complex revealed that the mutated residue was unlikely to interact directly with the oxazolidinone binding site. This is the first time that rpoB mutation has been associated with resistance to the PhLOPSa antimicrobials.

[1]  L. Peixe,et al.  Dissemination of Staphylococcus epidermidis ST22 With Stable, High-Level Resistance to Linezolid and Tedizolid in the Greek-Turkish Region (2008–2016) , 2018, Infection Control & Hospital Epidemiology.

[2]  J. Shendure,et al.  Correction: A Year of Infection in the Intensive Care Unit: Prospective Whole Genome Sequencing of Bacterial Clinical Isolates Reveals Cryptic Transmissions and Novel Microbiota , 2017, PLoS genetics.

[3]  Yang Zhang,et al.  Protein Structure and Function Prediction Using I‐TASSER , 2015, Current protocols in bioinformatics.

[4]  L. E. Thomsen,et al.  Stepwise Decrease in Daptomycin Susceptibility in Clinical Staphylococcus aureus Isolates Associated with an Initial Mutation in rpoB and a Compensatory Inactivation of the clpX Gene , 2015, Antimicrobial Agents and Chemotherapy.

[5]  X. Xia,et al.  A novel gene, optrA, that confers transferable resistance to oxazolidinones and phenicols and its presence in Enterococcus faecalis and Enterococcus faecium of human and animal origin. , 2015, The Journal of antimicrobial chemotherapy.

[6]  Stephen J. Salipante,et al.  A Year of Infection in the Intensive Care Unit: Prospective Whole Genome Sequencing of Bacterial Clinical Isolates Reveals Cryptic Transmissions and Novel Microbiota , 2015, PLoS genetics.

[7]  P. Alifano,et al.  Rifampicin-resistance, rpoB polymorphism and RNA polymerase genetic engineering. , 2015, Journal of biotechnology.

[8]  Hanine Mansour,et al.  Tedizolid: a new oxazolidinone antimicrobial. , 2014, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[9]  Xin Zhou,et al.  Molecular characterization of rifampicin-resistant Staphylococcus aureus isolates in a Chinese teaching hospital from Anhui, China , 2012, BMC Microbiology.

[10]  L. Cui,et al.  Impact of rpoB Mutations on Reduced Vancomycin Susceptibility in Staphylococcus aureus , 2011, Journal of Clinical Microbiology.

[11]  Edward H. Lee.  American society of health-system pharmacists. , 2011, P & T : a peer-reviewed journal for formulary management.

[12]  M. Fukuda,et al.  An RpoB Mutation Confers Dual Heteroresistance to Daptomycin and Vancomycin in Staphylococcus aureus , 2010, Antimicrobial Agents and Chemotherapy.

[13]  M. Hilgers,et al.  Novel Ribosomal Mutations in Staphylococcus aureus Strains Identified through Selection with the Oxazolidinones Linezolid and Torezolid (TR-700) , 2009, Antimicrobial Agents and Chemotherapy.

[14]  J. Finn,et al.  In Vitro Activity of TR-700, the Antibacterial Moiety of the Prodrug TR-701, against Linezolid-Resistant Strains , 2008, Antimicrobial Agents and Chemotherapy.

[15]  A. MacGowan,et al.  A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. , 2001, The Journal of antimicrobial chemotherapy.